EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Antibody-Mimicking Nanocluster Ameliorates Osteoporosis in Preclinical Model

Qing Yuan, Qiao-Zhi Li, Zhichao Zhang, Dongfang Xia, Haoran Dang, Liming Wang, Wenchao Niu, Zhen Chen, Liang Gao, Lina Zhao, Kai Cao, Xingfa Gao, Xueyun Gao

ACS Nano Medicine · 2026-11-11 · 1 (10) · 2716-2729

DOI: 10.1021/acsnanomed.6c00201 ↗
AbstractBibliografische Angaben

Abstract

Abstract Osteoporosis occurs due to the synergistic effect of increased bone resorption and decreased bone formation. However, a therapeutic approach that can simultaneously inhibit osteoclastic resorption and promote osteogenic activity directly is still lacking. Growing evidence demonstrates the I-kappaB kinase beta (IKKβ)-mediated NF-κB activation is a common crucial regulator in differentiation of both osteoclasts and osteoblasts. Herein, we screened a peptide-coated gold nanocluster (GA) and further disclosed that the optimized GA works like an antibody to block IKKβ activation well. The GA can simultaneously inhibit IKKβ-mediated osteoclastogenesis and enhances osteoblastic mineralization in vitro and effectively ameliorates osteoporosis in a preclinical model in a safe manner. Compared with first-line antiresorptive alendronate (ALN, suppress bone resorption only), GA significantly promotes bone formation and improves the quality of bone microarchitecture in vivo. These data suggest that antibody-like GAs hold great potential in osteoporosis therapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →